AvantGen is a privately-held biotechnology company developing next-generation therapeutic antibodies.

As a leader in yeast-based novel human antibody discovery, antibody humanization, antibody affinity maturation and optimization, AvantGen has developed a proprietary yeast display system, a proprietary fully human antibody (Germliner™) library and screening technologies.

Using this unique technology platform, AvantGen is rapidly expanding its pipeline in the areas of inflammation, cardiovascular disease, and oncology.

AvantGen collaborates with pharmaceutical and biotechnology companies to facilitate and speed their path to antibody-based therapeutic development through partnerships and licensing.

AvantGen also collaborates with the National Institutes of Health (NIH) to develop novel and renewable affinity captures for proteomic studies.